Related references
Note: Only part of the references are listed.Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?
Veronica Melchionda et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Clinical and Microbiologic Outcomes in Patients Receiving Treatment for Mycobacterium abscessus Pulmonary Disease
Julie Jarand et al.
CLINICAL INFECTIOUS DISEASES (2011)
Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice
Ann Sturdy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs
Jiwon Lyu et al.
RESPIRATORY MEDICINE (2011)
Nontuberculous Mycobacterial Lung Disease Prevalence at Four Integrated Health Care Delivery Systems
D. Rebecca Prevots et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Changing Epidemiology of Pulmonary Nontuberculous Mycobacteria Infections
Rachel M. Thomson
EMERGING INFECTIOUS DISEASES (2010)
Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin
Paul Mick et al.
JOURNAL OF OTOLARYNGOLOGY (2007)
An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
David E. Griffith et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Irreversible sensorineural hearing loss due to clarithromycin
J Coulston et al.
POSTGRADUATE MEDICAL JOURNAL (2005)
Aminoglycoside toxicity: Daily versus thrice-weekly dosing for treatment of mycobacterial diseases
CA Peloquin et al.
CLINICAL INFECTIOUS DISEASES (2004)
Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine
SK Field et al.
CHEST (2003)
Share Paper
